Comparing the effectiveness of revascularization interventions with medical therapy in patients with ischemic cardiomyopathy: A systematic review and meta-analysis

Background: Determining the effectiveness of cardiovascular interventions plays an important role in reimbursement decisions, health care pricing, and providing clinical guidance on the use of existing clinical technologies. This study aimed to review and analyze the effectiveness of revascularization interventions (CABG and PCI) compared to medical therapy in patients with ischemic cardiomyopathy. Methods: Different databases were searched up to December 2017. The articles were selected based on inclusion and exclusion criteria. Quality of all studies was evaluated by Jadad score and relevant checklists. The I2 test was used to test heterogeneity. Also, to integrate the results of similar studies, meta-analysis was done using STATA software. Results: A total of 18 studies were included. Based on the random effects model, the overall results of comparing the effectiveness of revascularization interventions with medical therapy were as follow: 38.94 [95% CI: 26.95-50.94, p<0.001, I2 = 99.6%, p<0.001], [75.31, 95% CI: 74.06-76.57, p<0.001, I2= 88.8, p<0.001], and 75.76 [95% CI: 71.99-79.53, p<0.001, I2= 99.2, p<0.001] for cardiac mortality rate, quality of life, and 5-year survival, respectively. Also, in patient satisfaction index, revascularization interventions were shown to be more effective than medical therapy. Conclusion: This study showed that revascularization interventions in all studied indices were more effective than medical therapy. Also, between revascularization interventions, PCI was more effective in cardiovascular mortality and 5-year survival than CABG in terms of quality of life. Moreover, CABG was more effective than PCI. In patient satisfaction index, the results of the 2 included studies were contradictory.

[1]  V. Alipour,et al.  Effectiveness of revascularization interventions compared with medical therapy in patients with ischemic cardiomyopathy , 2018, Medicine.

[2]  A. Boyle,et al.  Percutaneous coronary intervention versus coronary artery bypass grafting in heart transplant recipients with coronary allograft vasculopathy: a systematic review and meta-analysis of 1,520 patients. , 2018, Annals of cardiothoracic surgery.

[3]  Yang Ting Ju,et al.  Utility and quality-adjusted life-years in coronary artery disease , 2017, Medicine.

[4]  J. Panza,et al.  Surgical Revascularization in Older Adults with Ischemic Cardiomyopathy. , 2017, Heart failure clinics.

[5]  O. Schillaci,et al.  Impact of coronary revascularization on the clinical and scintigraphic outlook of patients with myocardial ischemia , 2017, Journal of cardiovascular medicine.

[6]  A. Marui.  Coronary-artery bypass surgery plus medical therapy is associated with longer survival over 10 years than medical therapy alone in patients with ischaemic cardiomyopathy , 2016, Evidence-Based Medicine.

[7]  Hosein Shabaninejad,et al.  A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis , 2016, Expert review of clinical immunology.

[8]  C. Ayers,et al.  Impact of Chronic Total Occlusions and Coronary Revascularization on All-Cause Mortality and the Incidence of Ventricular Arrhythmias in Patients With Ischemic Cardiomyopathy. , 2015, The American journal of cardiology.

[9]  W. Weintraub,et al.  Revascularization vs. Medical Therapy in Stable Ischemic Heart Disease. , 2015, Progress in cardiovascular diseases.

[10]  Kristian Thorlund,et al.  The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations , 2015, Annals of Internal Medicine.

[11]  P. Austin,et al.  Comparative-Effectiveness of Revascularization Versus Routine Medical Therapy for Stable Ischemic Heart Disease: A Population-Based Study , 2014, Journal of General Internal Medicine.

[12]  Peyman Rezaei Hachesu,et al.  Evidence‐based medicine: going beyond improving care provider viewpoints, using and challenges upcoming , 2014, Journal of evidence-based medicine.

[13]  I. Piña,et al.  The STICH trial (Surgical Treatment for Ischemic Heart Failure): mode-of-death results. , 2013, JACC. Heart failure.

[14]  C. Grines,et al.  Effect of percutaneous coronary intervention on quality of life: A consensus statement from the society for cardiovascular angiography and interventions , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[15]  M. Desai,et al.  Survival in Patients With Severe Ischemic Cardiomyopathy Undergoing Revascularization Versus Medical Therapy: Association With End-Systolic Volume and Viability , 2012, Circulation.

[16]  S. Bangalore,et al.  Percutaneous Coronary Intervention Versus Optimal Medical Therapy in Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials , 2012, Circulation. Cardiovascular interventions.

[17]  E. Yow,et al.  Long-term survival of patients with ischemic cardiomyopathy treated by coronary artery bypass grafting versus medical therapy. , 2012, The Annals of thoracic surgery.

[18]  B. Gersh,et al.  A Randomized Controlled Clinical Trial of 3 Therapeutic Strategies for Multivessel Coronary Artery Disease , 2010 .

[19]  J. Hartikainen,et al.  Health‐Related Quality of Life After Coronary Artery Bypass Grafting: A Review of Randomized Controlled Trials , 2010, Journal of cardiac surgery.

[20]  Thomas A Trikalinos,et al.  Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis , 2009, The Lancet.

[21]  Adnan Kastrati,et al.  A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. , 2008, Journal of the American College of Cardiology.

[22]  Bjarni E Pjetursson,et al.  A systematic review of the survival and complication rates of resin-bonded bridges after an observation period of at least 5 years , 2008, BDJ.

[23]  Reza Ardehali,et al.  Systematic Review: The Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Graft Surgery , 2007, Annals of Internal Medicine.

[24]  D. Berman,et al.  Optimal medical therapy with or without PCI for stable coronary disease. , 2007, The New England journal of medicine.

[25]  J. Kaski,et al.  Role of trimetazidine in management of ischemic cardiomyopathy. , 2006, The American journal of cardiology.

[26]  W. Ghali,et al.  Quality of life after coronary revascularization in the elderly. , 2006, European heart journal.

[27]  Tania B. Huedo-Medina,et al.  Assessing heterogeneity in meta-analysis: Q statistic or I2 index? , 2006, Psychological methods.

[28]  William C Stanley,et al.  Myocardial substrate metabolism in the normal and failing heart. , 2005, Physiological reviews.

[29]  M. Pfisterer,et al.  Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease. Findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME). , 2004, European heart journal.

[30]  Mark A Hlatky,et al.  Medical Costs and Quality of Life 10 to 12 Years After Randomization to Angioplasty or Bypass Surgery for Multivessel Coronary Artery Disease , 2004, Circulation.

[31]  R. Califf,et al.  Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank). , 2002, The American journal of cardiology.

[32]  W. Ghali,et al.  Survival After Coronary Revascularization in the Elderly , 2002, Circulation.

[33]  J. Fleshman,et al.  Fecal incontinence quality of life scale , 2000, Diseases of the colon and rectum.

[34]  D. Clark,et al.  Development of a stroke-specific quality of life scale. , 1999, Stroke.

[35]  J. Cleland,et al.  Is medical treatment for angina the most cost-effective option? , 1997, European heart journal.

[36]  J. Jamison.  PATIENT SATISFACTION , 1996, Australasian Chiropractic & Osteopathy.

[37]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[38]  S. Wilson.  Methods for the economic evaluation of health care programmes , 1987 .

[39]  Christopher McCabe,et al.  Cost Effectiveness Modelling for Health Technology Assessment , 2015 .

[40]  Asphalt Pavement Mixes,et al.  DEVELOPMENT OF A , 2011 .

[41]  C. O'connor,et al.  Revascularization improves survival in ischemic cardiomyopathy regardless of electrocardiographic criteria for prior small-to-medium myocardial infarcts. , 2002, American heart journal.

[42]  K. Jolly,et al.  Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review. , 2000, Health technology assessment.